Cancer News and Research

Latest Cancer News and Research

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

29 Oct 2010

Bioniche ranked #14 on Top 50 Best Small and Medium Employers in Canada

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, is pleased to be named among the Top 50 Best Small and Medium Employers in Canada. Bioniche was ranked number 14 by its employees. Two years ago, the Company attained a 13th place ranking.

28 Oct 2010

Pro-Pharmaceuticals ships first commercial order of DAVANAT to PROCAPS in Colombia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has shipped its first commercial order of DAVANAT® to PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. The $200,000 shipment of DAVANAT® will be used by PROCAPS to qualify its vial filling process.

28 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

NeoGenomics third quarter revenue grows 19% to $8.7 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the third quarter 2010.

28 Oct 2010

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Antigenics Inc. reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009.

28 Oct 2010

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation announced non-GAAP net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010.

28 Oct 2010

New oncology training program for registered nurses in Ghana

The National Cancer Coalition (NCC) and the Ghana based organization Breast Care International (BCI) are pleased to announce the successful implementation of their oncology training program for registered nurses in Ghana. The program was officially sponsored by the US headquartered Johnson & Johnson and focuses on early detection of breast and cervical cancers for improved survival outcomes.

28 Oct 2010

New nationwide initiative to conduct research on human immune system

A new nationwide research initiative has been launched to define changes in the human immune system's response to infection and vaccination using human rather than animal models, which could lead to better vaccines and other treatments. Baylor Research Institute (BRI), along with five other U.S.-based Human Immune Phenotyping Centers, will receive a total of $100 million over five years to conduct the research.

28 Oct 2010

BioCryst 2010 third quarter revenue increases from $10.5 million to $12.0 million

BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter and nine months ended September 30, 2010.

28 Oct 2010

IsoRay completes Cs-131 brachytherapy seeds feasibility study for breast cancer treatment

IsoRay, Inc. announced, today, it has completed an initial feasibility study, which demonstrates the ability to use its patented Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) in accelerated partial breast irradiation (APBI) for breast cancer treatment.

28 Oct 2010

Future of health reform legislation and voting for Congressional elections

A comprehensive review of national opinion polls, including newly released data, shows that those who say they intend to vote for a Democratic congressional candidate in 2010 and those who say they intend to vote for a Republican in their district hold starkly different views of what they want the future of health reform legislation to be, mirroring the divide between Democratic and Republican leaders in Congress on this issue.

28 Oct 2010

Researchers explore knowledge of palliative care oncologists with respect to genetic testing

If you were dying from cancer, would you consider genetic testing. A recent study conducted by researchers from Virginia Commonwealth University Massey Cancer Center showed that most terminally ill cancer patients who were eligible for genetic testing never received it despite that it could potentially save a relative's life.

28 Oct 2010

Pancreatic cancer develops and spreads more slowly than thought before

Pancreatic cancer develops and spreads much more slowly than scientists have thought, according to new research from Johns Hopkins investigators. The finding indicates that there is a potentially broad window for diagnosis and prevention of the disease.

28 Oct 2010

World's largest research initiative to mutate all mouse genes

The world's largest research initiative to mutate all mouse genes is now able to reach the summit because the ambitious EUCOMMTOOLS project started on October 1, 2010. This project is being coordinated by Helmholtz Zentrum München and will finalize the groundwork for the analysis of all mouse gene functions. The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer.

28 Oct 2010

Max Planck Innovation licenses new software for metabolite analysis

Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.

28 Oct 2010

Cord Blood America enters new work agreement with Hawaii Medical Service Association

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells to families nationwide and internationally, is pleased to announce a new work agreement with the Hawaii Medical Service Association (HMSA), an independent licensee of the Blue Cross and Blue Shield Association, the largest and most experienced provider of health care coverage in Hawaii.

28 Oct 2010

Government institutions need to find alternate funding sources for colorectal cancer screening

Offering colorectal cancer screening to poor minority women during mammography visits can effectively expand screening in this otherwise underserved population, although lack of medical insurance remains a significant barrier. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The results highlight the need to find alternative funding sources for colorectal cancer screening from the government or private institutions.

28 Oct 2010

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.

28 Oct 2010

Scientists suggest FDA to reevaluate safety of plant-based antioxidants

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants including those renowned for their apparent ability to prevent cancer may actually aggravate or even cause cancer in some individuals.

28 Oct 2010